Conversely, mTORC1 inhibitors are in clinical trials for various cancer types [47, 48]; everolimus was approved for hormone receptor-positive breast cancer [49], and more recently used for HER2 + tumours [50, 51]. The gene discussed is ERBB2; the disease is neoplasm.